Houlihan Financial Resource Group Ltd. Sells 1,659 Shares of Amgen Inc. $AMGN

Houlihan Financial Resource Group Ltd. cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 49.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,697 shares of the medical research company’s stock after selling 1,659 shares during the period. Houlihan Financial Resource Group Ltd.’s holdings in Amgen were worth $479,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Legacy Investment Solutions LLC acquired a new stake in Amgen during the 2nd quarter worth $27,000. Evelyn Partners Investment Management LLP bought a new position in shares of Amgen in the 2nd quarter worth $32,000. Howard Hughes Medical Institute acquired a new stake in shares of Amgen during the second quarter worth $32,000. Quaker Wealth Management LLC grew its stake in shares of Amgen by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after purchasing an additional 240 shares during the period. Finally, Nvwm LLC increased its holdings in Amgen by 893.3% in the second quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 134 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a report on Tuesday, November 11th. Daiwa Capital Markets increased their target price on shares of Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Cantor Fitzgerald boosted their price target on shares of Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Finally, Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average target price of $339.45.

Amgen Stock Performance

AMGN opened at $330.03 on Friday. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The company has a market capitalization of $177.71 billion, a price-to-earnings ratio of 25.50, a P/E/G ratio of 2.93 and a beta of 0.45. The business’s 50-day moving average price is $331.36 and its two-hundred day moving average price is $305.66. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $346.38.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same quarter last year, the firm earned $5.58 EPS. Amgen’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Insider Activity

In related news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 10,908 shares of company stock worth $3,674,966 in the last quarter. Corporate insiders own 0.76% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.